Dove Medical Press Ltd is an online open access academic publisher specialising in science, technology and especially medicine. All 80 peer-reviewed journals are free to access online, allowing authors to disseminate their research to a global audience. Most of our journals are widely indexed in databases such as PubMed, Scopus and DOAJ, and an increasing number have Impact Factors. We are a member of OASPA, COPE and HINARI, and are committed to publishing good scientific research and giving authors around the world the opportunity to publish and share their research findings. We have an efficient and rigorous peer-review process. Due to this, many of our journals are able to provide authors with an initial editorial decision within four to five weeks. We aim to provide the highest possible standard of service to our authors. Recent feedback from an author survey demonstrated that: • 100% of authors surveyed found the online manuscript system easy to use • 100% of authors surveyed agreed that they received professional accurate service • 97% of authors surveyed would submit a manuscript with us again • 96% of authors surveyed received prompt communication throughout the publishing process • 86% of authors surveyed rated their level of satisfaction as Excellent (the other 14% rated us as good) To view testimonials from more of our authors please visit: https://www.dovepress.com/testimonials.php We have offices in the United Kingdom, USA and New Zealand. Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC.
1 signal in the last 90 days.
The order this company entered each market — oldest to newest
Harbour BioMed announces positive Phase I results for HBM9378
Sign up to see the full signal feed
How Dove Medical Press's international expansion compares to its competitors
Dove Medical PressYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Dove Medical PressYou | 1 | 1 | -100% | 1 | 11 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Harbour BioMed's Phase I trial of HBM9378, a novel antibody targeting TSLP, shows favorable safety and extended half-life, supporting further development for severe immunological disorders.
Study finds combining ESR and CRP tests reduces misdiagnoses and saves $9.95 million annually for a 739-bed hospital, challenging calls to eliminate ESR testing.
Peer-reviewed study shows combined ESR and CRP testing reduces misdiagnoses and saves costs compared to CRP alone in inflammatory conditions.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Dove Medical Press's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
